FORM OF AMENDED AND RESTATED INDEMNIFICATION AGREEMENTIndemnification Agreement • October 7th, 2014 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 2014 between PROTEON THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
Proteon Therapeutics, Inc. Waltham, MA 02451 October 1, 2014Employment Agreement • October 7th, 2014 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
Reference is hereby made to that certain Employment Letter Agreement (the “Original Employment Agreement”), dated as of September 9, 2013, between you and Proteon Therapeutics, Inc. (the “Company” or “Proteon”). This letter agreement (the “Agreement”) amends and restates the Original Employment Agreement in its entirety. This letter contains the basic terms of your employment with the Company. If you agree to the terms and conditions set forth in this offer letter, please sign at the end of this letter in the space indicated. This Agreement shall be effective contingent upon, and from and after, the consummation of the Company’s initial public offering (the “IPO”) of its common stock, par value $0.001 per share (“Common Stock”).
UNDERWRITING AGREEMENT [Number of Firm Shares] Shares Proteon Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 7th, 2014 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Proteon Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”), an aggregate of [·] shares (the “Firm Shares”) of the common stock, par value $0.001 per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional [·] shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares”.
